Xinjing Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xinjing Zhao has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Guoyu Zhou
Department of Geriatric Medicine , Qilu Hospital of Shandong University , Jinan , China , qiluhospital.com
1 shared publication- Jing Han
Department of Acupuncture, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
1 shared publication - Lin Tian
Acupuncture and Tuina College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People’s Republic of China
1 shared publication - Shengfeng Wang
Department of Epidemiology and Biostatistics, School of Public Health, Peking University
1 shared publication - Shuo Feng
Department of Neurology, Qilu Hospital of Shandong University, Jinan, Shandong, China
1 shared publication - Tian-Yu Gao
Department of neurology, Qilu Hospital of Shandong University, Jinan, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Pain Research and Management
- Vol. 2026 (1) , 9739777
Lifetime Probability of Developing Migraine: A Novel Epidemiological Perspective Based on Global Burden of Disease Data
Migraine affects over one billion people worldwide and imposes substantial burdens, yet the lifetime risk of developing migraine has been understudied. Using Global Burden of Disease 2021 data, we estimated age‐, sex‐, and location‐specific lifetime probabilities with the adjusted‐for‐multiple‐primaries method, which accounts for competing mortality and life expectancy. Trends were quantified by average annual percentage change, socioeconomic inequality by concentration indices, and future trajectories with autoregressive integrated moving average models. In 2021, the global lifetime probability of migraine was 51.53% (95% CI: 51.51%–51.55%); females faced a higher risk than males (59.84% vs. 41.99%; ratio: 1.42). Regional estimates ranged from 60.58% in Western Europe to 35.63% in Eastern Sub‐Saharan Africa, paralleling the sociodemographic index gradient (high SDI 55.74% vs. low SDI 45.13%). Risk accumulated mainly during early and middle adulthood. The concentration index declined from 0.35 in 1990 to 0.27 in 2021, indicating reduced socioeconomic disparities, while projections suggest global lifetime risk will rise to 57.18% by 2050. Roughly half the world’s population is therefore expected to experience migraine during their lives, with pronounced heterogeneity by sex, region, and socioeconomic level, underscoring the need for targeted public‐health strategies, particularly for younger individuals during high‐riskperiods.
- 1 January 2026
- Published by Wiley in Pain Research and Management
- Vol. 2026 (1) , 9739777
Open AccessLifetime Probability of Developing Migraine: A Novel Epidemiological Perspective Based on Global Burden of Disease Data
Migraine affects over one billion people worldwide and imposes substantial burdens, yet the lifetime risk of developing migraine has been understudied. Using Global Burden of Disease 2021 data, we estimated age‐, sex‐, and location‐specific lifetime probabilities with the adjusted‐for‐multiple‐primaries method, which accounts for competing mortality and life expectancy. Trends were quantified by average annual percentage change, socioeconomic inequality by concentration indices, and future trajectories with autoregressive integrated moving average models. In 2021, the global lifetime probability of migraine was 51.53% (95% CI: 51.51%–51.55%); females faced a higher risk than males (59.84% vs. 41.99%; ratio: 1.42). Regional estimates ranged from 60.58% in Western Europe to 35.63% in Eastern Sub‐Saharan Africa, paralleling the sociodemographic index gradient (high SDI 55.74% vs. low SDI 45.13%). Risk accumulated mainly during early and middle adulthood. The concentration index declined from 0.35 in 1990 to 0.27 in 2021, indicating reduced socioeconomic disparities, while projections suggest global lifetime risk will rise to 57.18% by 2050. Roughly half the world’s population is therefore expected to experience migraine during their lives, with pronounced heterogeneity by sex, region, and socioeconomic level, underscoring the need for targeted public‐health strategies, particularly for younger individuals during high‐riskperiods.